Ahuja Nita reported grant involving 318 derivative units of ABBOTT LABORATORIES at $98.83 for $31.4k on Sep 30, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed Oct 2, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$31,427.94Shares × reported price
Shares traded
318Stock Equivalent Units
Price per share
$98.83Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
771Direct
Trade date
Sep 30, 2026Grant
Filed
Oct 2, 2026, 4:10 PM ET2-day reporting delay
Accession
0001104659-26-113285Code A · Transaction 234449
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

ABT price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ABT · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +13%1w ago +6.1%1d ago +3.5%
Returns since7d +2.2%30d +5.7%90d180d1y

Footnotes in full

F1: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.